Service Provision in the Wake of a New Funding Model for Community Pharmacy

Overview

Journal BMC Health Serv Res

Publisher Biomed Central

Specialty Health Services

Date 2018 May 3

PMID 29716610

Citations 18

Authors

Alesha J Smith

Shane L Scahill

Jeff Harrison

Tilley Carroll

Natalie J Medlicott

Affiliations

Soon will be listed here.

Abstract

Background: Recently, New Zealand has taken a system wide approach providing the biggest reform to New Zealand community pharmacy for 70 years with the aim of providing more clinically orientated patient centred services through a new funding model. The aim of this study was to understand the types of services offered in New Zealand community pharmacies since introduction of the new funding model, what the barriers are to providing these services.

Method: A survey of all community pharmacies were undertaken between August, 2014 and February, 2015. Basic descriptive statistics were completed and group comparisons were made using the chi squared test with significance set at p < 0.05.

Results: 528 responses were received. Education and advice on prescription and non-prescription medicines were the two top listed services provided. There were no significant differences in service provision between rural and metro based pharmacies. Many pharmacies were considering introducing new patient centred services. Four of the top ten frequently provided services have no public funding attached. Costs and staff availability are the most common barriers to undertake services, more predominantly in patient centred services.

Conclusion: This study was the first to provide an evaluation of service provision in response to a new funding model for New Zealand Community Pharmacies. A broad range of services are being undertaken in New Zealand community pharmacies including patient-centred services. A number of barriers to service provision were identified. This study provides a baseline for the current levels of service provision upon which future studies can compare to and evaluate any changes in service provision with differing funding models going forward.

Citing Articles

Changes in provision of extended community pharmacy services in Aotearoa New Zealand, 2018 to 2022.

Officer T, McDonald J, Jeffreys M, Cumming J, Russell L, McKinlay E BMC Health Serv Res. 2024; 24(1):1571.

PMID: 39696269 PMC: 11653777. DOI: 10.1186/s12913-024-11948-3.

Developing a quality framework for community pharmacy: a systematic review of international literature.

Hindi A, Campbell S, Jacobs S, Schafheutle E BMJ Open. 2024; 14(2):e079820.

PMID: 38365299 PMC: 10875530. DOI: 10.1136/bmjopen-2023-079820.

Self-care in New Zealand: The role of the community pharmacy.

Abdul Aziz Y, Heydon S Explor Res Clin Soc Pharm. 2023; 12:100374.

PMID: 38074836 PMC: 10709159. DOI: 10.1016/j.rcsop.2023.100374.

Assessing consumers' perception and demand on the community pharmacists' dispensing.

Xuan Y, Goh H, Rehman I, Shafqat N, Al-Worafi Y, Ming L J Pharm Policy Pract. 2023; 16(1):162.

PMID: 38031133 PMC: 10685624. DOI: 10.1186/s40545-023-00609-1.

Community pharmacists' views about prescription medicine co-payments and potential implications for equitable access to medicines: a critical realist interpretation.

Peacocke E, Fusheini A, Norris P J Pharm Policy Pract. 2023; 16(1):156.

PMID: 38012721 PMC: 10680315. DOI: 10.1186/s40545-023-00673-7.

References

Saramunee K, Krska J, Mackridge A, Richards J, Suttajit S, Phillips-Howard P . How to enhance public health service utilization in community pharmacy?: general public and health providers' perspectives. Res Social Adm Pharm. 2012; 10(2):272-84. DOI: 10.1016/j.sapharm.2012.05.006. View

Hatah E, Braund R, Tordoff J, Duffull S . A systematic review and meta-analysis of pharmacist-led fee-for-services medication review. Br J Clin Pharmacol. 2013; 77(1):102-15. PMC: 3895351. DOI: 10.1111/bcp.12140. View

Petrakaki D, Barber N, Waring J . The possibilities of technology in shaping healthcare professionals: (re/de-)professionalisation of pharmacists in England. Soc Sci Med. 2012; 75(2):429-37. DOI: 10.1016/j.socscimed.2012.03.033. View

Scahill S, Harrison J, Carswell P, Shaw J . Health care policy and community pharmacy: implications for the New Zealand primary health care sector. N Z Med J. 2010; 123(1317):41-51. View

Law K, Aranda K . The shifting foundations of nursing. Nurse Educ Today. 2009; 30(6):544-7. DOI: 10.1016/j.nedt.2009.11.006. View

Roberts A, Benrimoj S, Chen T, Williams K, Aslani P . Practice change in community pharmacy: quantification of facilitators. Ann Pharmacother. 2008; 42(6):861-8. DOI: 10.1345/aph.1K617. View

Hattingh H, Emmerton L, Ng Cheong Tin P, Green C . Utilization of community pharmacy space to enhance privacy: a qualitative study. Health Expect. 2015; 19(5):1098-110. PMC: 5152744. DOI: 10.1111/hex.12401. View

Scahill S . Placing "culture" at the center of social pharmacy practice and research. Res Social Adm Pharm. 2012; 9(1):1-3. DOI: 10.1016/j.sapharm.2012.05.008. View

Petersen L, Woodard L, Urech T, Daw C, Sookanan S . Does pay-for-performance improve the quality of health care?. Ann Intern Med. 2006; 145(4):265-72. DOI: 10.7326/0003-4819-145-4-200608150-00006. View

10.

Kinsey H, Scahill S, Bye L, Harrison J . Funding for change: New Zealand pharmacists' views on, and experiences of, the community pharmacy services agreement. Int J Pharm Pract. 2016; 24(6):379-389. DOI: 10.1111/ijpp.12266. View

11.

Blenkinsopp A, Anderson C, Armstrong M . Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Public Health Med. 2003; 25(2):144-53. DOI: 10.1093/pubmed/fdg030. View

12.

Mak V, Clark A, March G, Gilbert A . The Australian pharmacist workforce: employment status, practice profile and job satisfaction. Aust Health Rev. 2012; 37(1):127-30. DOI: 10.1071/AH12180. View

13.

Mossialos E, Courtin E, Naci H, Benrimoj S, Bouvy M, Farris K . From "retailers" to health care providers: Transforming the role of community pharmacists in chronic disease management. Health Policy. 2015; 119(5):628-39. DOI: 10.1016/j.healthpol.2015.02.007. View

14.

Schoen C, Osborn R, Doty M, Bishop M, Peugh J, Murukutla N . Toward higher-performance health systems: adults' health care experiences in seven countries, 2007. Health Aff (Millwood). 2007; 26(6):w717-34. DOI: 10.1377/hlthaff.26.6.w717. View

15.

Bush J, Langley C, Wilson K . The corporatization of community pharmacy: implications for service provision, the public health function, and pharmacy's claims to professional status in the United Kingdom. Res Social Adm Pharm. 2009; 5(4):305-18. DOI: 10.1016/j.sapharm.2009.01.003. View

16.

Bernsten C, Andersson K, Gariepy Y, Simoens S . A comparative analysis of remuneration models for pharmaceutical professional services. Health Policy. 2009; 95(1):1-9. DOI: 10.1016/j.healthpol.2009.11.008. View

17.

Noyce P . Providing patient care through community pharmacies in the UK: policy, practice, and research. Ann Pharmacother. 2007; 41(5):861-8. DOI: 10.1345/aph.1K015. View

18.

Feletto E, Wilson L, Roberts A, Benrimoj S . Building capacity to implement cognitive pharmaceutical services: Quantifying the needs of community pharmacies. Res Social Adm Pharm. 2010; 6(3):163-73. DOI: 10.1016/j.sapharm.2009.08.003. View

19.

Boechler L, Despins R, Holmes J, Northey J, Sinclair C, Walliser M . Advocacy in pharmacy: Changing "what is" into "what should be". Can Pharm J (Ott). 2015; 148(3):138-41. PMC: 4483753. DOI: 10.1177/1715163515577693. View

20.

Scahill S, Harrison J, Sheridan J . The ABC of New Zealand's ten year vision for pharmacists: awareness, barriers and consultation. Int J Pharm Pract. 2010; 17(3):135-42. View